Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Pliant Therapeutics reported a Q2 net loss of $22.4 million, significantly lower than the prior year's $43.3 million, driven by reduced headcount and the termination of the bexotegrast program. The company ended the quarter with $159.6 million in cash and investments, sufficient to fund operations into the second half of 2028, while the Phase 1b FORTIFY trial for PLN-101095 continues to enroll ahead of schedule. Pliant bolstered its leadership by appointing Dr. Flavia Borellini and Dr.
Key figures
- Runway
- second half of 2028
- Net loss
- $22.4 million
- Ga expense
- $7.1 million
- Rd expense
- $16.7 million
- Cash position
- $159.6 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.